Baqsimi started contributing to Amphastar’s revenues in the third quarter of 2023. The company’s fourth-quarter revenues are expected to have been driven by the sales of its high-margin ...

Amphastar Pharmaceuticals ... and France. It offers BAQSIMI, a nasal spray for the treatment of severe hypoglycemia; Primatene Mist, an over-the-counter epinephrine inhalation product for the ...

In Q3 2024, Amphastar Pharmaceuticals ... driven by strong sales of products like Primatene Mist ($26.1 million), BAQSIMI ($40.4 million), and the launch of Albuterol MDI. Primatene Mist is ...

It isn’t known whether Baqsimi (glucagon) is safe to use while pregnant or breastfeeding. Certain factors, including the risks of not treating your condition during pregnancy, may determine ...

Geode Capital Management LLC increased its stake in shares of Amphastar Pharmaceuticals, Inc. (NASDAQ:AMPH – Free Report) by ...

JP Morgan Shows Most Interest In Teva, Organon As Specialty Pharma Sector Exhibits Signs Of Stability JP Morgan assesses the specialty pharma sector, highlighting robust fundamentals and new ...